Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlobalData Plc    DATA   GB00B87ZTG26

GLOBALDATA PLC

(DATA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

GlobalData : Biogen's aducanumab in AD unlikely to be well-covered by payers, with FDA approval prospects mixed

11/23/2020 | 09:35pm EST
23 Nov 2020
Biogen's aducanumab in AD unlikely to be well-covered by payers, with FDA approval prospects mixed
Posted in Pharma

Following a controversial FDA Advisory Committee meeting for Biogen's aducanumab for mild Alzheimer's disease, where the panel members sharply recommended against approval, the therapy will likely face significant barriers to coverage if it gains an agency nod in March, according to reporting from William Newton, Pharma Writer for the Investigative News team at GlobalData, a leading data and analytics company.

Both Medicare and private insurance will likely be concerned by aducanumab's questionable efficacy, high cost of USD 50,000 a year that could be incurred for more than a decade, and safety concerns.

Newton states: 'High coinsurance requirements and stringent prior authorization, including expensive testing to determine eligibility, could mean far less than 10% of eligible patients take aducanumab if it gains FDA approval.'

Despite support for aducanumab in official FDA documents released prior to the FDA Advisory Committee hearing on the treatment, panelists were extremely critical of aducanumab and voted that it did not demonstrate efficacy in clinical trials. Given this contradictory signaling, experts Newton interviewed had no clear consensus over the likelihood of FDA approval.

The likely payer response to aducanumab, however, is clearer. Newton reports: 'Even if the FDA contradicts the advisory committee in its approval decision, the Center for Medicare Services officials are likely to pay close attention to panel member objections in making coverage decisions, including their questions regarding aducanumab's efficacy.'

Additionally, Medicare and private insurance will likely be concerned with the adverse event of amyloid-related imaging abnormalities seen in prior aducanumab studies. Newton states: 'Payers are likely to strongly weigh this well-established safety concern against the more unclear efficacy benefit when determining coverage plans.'

There is a potential way forward for aducanumab, even if the FDA does reject the application. Newton states: 'The FDA could require Biogen to complete a one-year study confirming aducanumab's effect on reducing amyloid count. The FDA could then approve aducanumab while requiring an additional postmarket study to confirm the surrogate marker of reduced amyloid count is clinically meaningful.'

Disclaimer

GlobalData plc published this content on 23 November 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 November 2020 02:34:01 UTC


© Publicnow 2020
All news about GLOBALDATA PLC
08:02aGLOBALDATA : Global economy expected to revive in 2021 due to vaccine rollout bu..
PU
08:02aGLOBALDATA : South Korea looks to strengthen position in global autonomous vehic..
PU
08:02aGLOBALDATA : Goldman Sachs was top M&A financial adviser by value and volume in ..
PU
08:02aGLOBALDATA : Wachtell Lipton Rosen & Katz and Kirkland & Ellis were the top M&A ..
PU
01/15GLOBALDATA : Demand for non-invasive genetic testing driving NIPT testing market..
PU
01/14GLOBALDATA : Tesco's record Christmas sales reveal how COVID-19 has boosted inte..
PU
01/14GLOBALDATA : Net-zero supply chains the future of FMCG as 84% of consumers globa..
PU
01/14GLOBALDATA : Absent online offer means Primark misses the mark during COVID-19 l..
PU
01/14GLOBALDATA : Card Factory's suffers amid store closures as it struggles compete ..
PU
01/14GLOBALDATA : Tesco's renewed focus on value provides base for stout Christmas tr..
PU
More news
Financials
Sales 2020 181 M 246 M 246 M
Net income 2020 23,0 M 31,2 M 31,2 M
Net Debt 2020 67,9 M 92,3 M 92,3 M
P/E ratio 2020 78,9x
Yield 2020 1,26%
Capitalization 1 475 M 2 005 M 2 004 M
EV / Sales 2020 8,52x
EV / Sales 2021 7,94x
Nbr of Employees 3 355
Free-Float 28,2%
Chart GLOBALDATA PLC
Duration : Period :
GlobalData Plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLOBALDATA PLC
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 1 535,67 GBX
Last Close Price 12,50 GBX
Spread / Highest target 13 820%
Spread / Average Target 12 185%
Spread / Lowest Target 9 500%
EPS Revisions
Managers and Directors
NameTitle
Michael Thomas Danson Chief Executive Officer & Director
Bernard Anthony Cragg Chairman
Graham Charles Lilley Chief Financial Officer, Secretary & Director
Peter Martin Harkness Independent Non-Executive Director
Murray Legg Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
GLOBALDATA PLC-8.42%2 019
S&P GLOBAL INC.-6.86%73 667
RELX PLC2.01%48 207
THOMSON REUTERS CORPORATION-4.74%39 023
WOLTERS KLUWER0.96%22 220
EQUIFAX INC.-7.89%21 607